Milgamma Mono 150 Dosage/Direction for Use

Posology: Adults: Unless otherwise prescribed, the usual dosage is 150 - 450 mg benfotiamine depending on the severity of the deficiency. Dosage recommendations are provided as follows. (See Table 1.)

Click on icon to see table/diagram/image

Milgamma mono 150 is initially taken over a period of at least 3 weeks. Thereafter maintenance treatment is governed by therapeutic response. In case of missing or insufficient therapeutic response after 4 weeks, therapy should be reconsidered.
Method of administration: Method and duration of administration: Benfotiamine 150 mg coated tablets should be swallowed whole with some fluid. The duration of administration is determined by the therapeutic response. Benfotiamine 150 mg coated tablets are initially taken over a period of at least 3 weeks in cases of vitamin B1 deficiency. Thereafter maintenance treatment is governed by therapeutic response with 150 or 300 mg benfotiamine (1-2 Benfotiamine 150 mg coated tablets). In case of missing or insufficient therapeutic response after 3 weeks in cases of vitamin B1 deficiency, therapy should be reconsidered.
Paediatric population: The safety and efficacy in children and adolescents up to 18 years have not been established. For this reason Milgamma mono 150 should not be used in children and adolescents below the age of 18 years.
Elderly: No dose adjustment is required for elderly patients.
Patients with renal impairment: No dose adjustment is required for patients with renal impairment.
Patients with hepatic impairment: No dose adjustment is required for patients with hepatic impairment.